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A B S T R A C T
Although there is evidence that diabetes affects seizure susceptibility, the underlying mechanism has
not been completely understood. Several studies also suggest a pivotal role for KATP channels in the
seizure modulation. The aim of the present study was to evaluate the seizure threshold induced by
pentylenetetrazole in diabetic mice at different times (3 days, 1–8 weeks) after induction of diabetes
with streptozocin and to examine the possible role of ATP-sensitive potassium (KATP) channels in this
manner.
Our data showed a time-dependent alteration in the threshold in diabetic mice, reaching a peak on
week 2 after streptozocin injection and declining signiﬁcantly afterwards. The seizure threshold in 8-
week diabetic mice was even lower than control levels, though the difference was not signiﬁcant. The
KATP channel opener cromakalim (0.1–30 mg/kg, i.p.) signiﬁcantly increased the seizure threshold in
control mice. Although the KATP channel blocker glibenclamide (0.5, 1 mg/kg) had no effect, it prevented
the effects of the potent dose of cromakalim (30 mg/kg) on seizure threshold in control mice.
Glibenclamide (1 mg/kg, i.p.) also decreased the seizure threshold in 2-week diabetic mice to the control
levels which was blocked by pre-treatment with cromakalim (10 mg/kg, i.p.). Cromakalim (10 mg/kg,
i.p.) signiﬁcantly increased the seizure threshold in 8-week diabetic mice which was inhibited by pre-
treatment with glibenclamide (1 mg/kg, i.p.).
We demonstrated a time-dependent alteration in the pentylenetetrazole-induced seizure threshold
in diabetic mice. This phenomenon might be due to the probable alteration in the KATP channel
functioning during the diabetic condition.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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ATP-sensitive K+ (KATP) channels exist in many excitable cells,
including cardiac myocytes, pancreatic b cells, muscle cells, and
neurons1,2 and are involved in several physiological functions.3,4
KATP channels are expressed pre- and post-synaptically in many
brain regions. They open and close in response to changes in
intracellular ATP/ADP ratios. Low ATP levels open these channels,
allowing K+ efﬂux and cell hyperpolarization.5 Therefore, the
activity of KATP channels is regulated by cell metabolism and* Corresponding author. Tel.: +98 21 6611 2802; fax: +98 21 6640 2569.
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doi:10.1016/j.seizure.2009.11.003provides a means of linking the electrical activity of a cell to its
metabolic state.6 Pharmacological studies have also demonstrated
that KATP channels play an important role in the control of seizure
threshold in several in vitro and in vivo models.3,7–12 Moreover, it
has been shown that mice lacking a subunit of KATP channels (Kir
6.2/ mice) are vulnerable to hypoxia, exhibiting a reduced
threshold for generalized seizure.9 Transgenic mice, overexpres-
sing the sulfonylurea receptor (SUR1) gene in the forebrain, show a
signiﬁcant increase in the threshold for kainite-induced seizures.13
Thus, physiopathologic conditions altering the KATP activation
could possibly affect the seizure threshold.
Diabetes mellitus affects over 350 million people worldwide
and 20 million people in the United States and the number of
people with diabetes is increasing by 5% per year.14 This condition
has profound effect on both central and peripheral nervous system
and disrupts normal cellular metabolism in many complication-
prone cell types and is especially damaging to neurons.15–18vier Ltd. All rights reserved.
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patients hyperglycemia can precipitate seizures.19–28 Some studies
also reported consistent results by using animal models of seizure.
In this regard, it was shown that alloxan-induced diabetic
hyperglycemia was associated with proconvulsant effects in the
electroshock seizure model in the adult rats29 and mice.30 Tutka et
al. also reported that bicuculline-induced seizure threshold is
signiﬁcantly decreased in streptozocin-induced diabetic mice.30
Although there is some evidence that hyperglycemia mainly
contributes to the alteration in the seizure threshold in diabetic
animals and patients,27,31,32 the underlying mechanism in this
phenomenon is as yet elusive.
In view the fact that KATP channels play a pivotal role in the
seizure threshold modulation, it would be reasonable if one
expected that KATP channels might be involved in the diabetes-
induced alteration in the seizure threshold. This assumption is in
agreement with the large amount of studies that have shown that
KATP channels functioning are affected by long-term diabetic
condition.33–37 For instance, it has been reported that relaxant
responses of basilar arteries to KATP channel openers is decreased
in the 12-week streptozocin (STZ)-induced diabetic rats.38,39
However, some studies have shown that the responses to KATP
channel activation were not altered or even increased in diabetic
vascular smooth muscle in the early experimental diabetic
state.40–43 According to the previous reports, it seems that the
duration of experimental diabetes could be an important factor
contributing to the observed effects of diabetes on the KATP channel
functioning. In this regard, we have recently demonstrated that
there is a time-dependent alteration in relaxant responses to the
KATP channel opener cromakalim in corpus cavernosum tissue
from STZ-induced diabetic rats.44 However, up to now it has not
been investigated the effect of duration of diabetes on the seizure
threshold and the role of KATP channels in this effect has not been
shown as yet. Therefore, the aim of the present study was to
investigate the effect of diabetic condition induced by STZ on the
seizure threshold in mice at different times after STZ injection and
to evaluate the role of KATP channels by using the speciﬁc KATP
channel blocker glibenclamide and the selective KATP channel
opener cromakalim in this manner. The seizure paradigm that we
usedwas the assessment of the clonic seizure threshold induced by
i.v. administration of the GABA receptor antagonist pentylenete-
trazole (PTZ). This paradigm represents an animal model of
seizures and is very sensitive to changes in seizure suscept-
ibility.45,46
2. Materials and methods
2.1. Chemicals
Drugs used were as follows: streptozocin (STZ; Sigma, St. Louis,
MO, USA), cromakalim, glibenclamide and pentylenetetrazole
(Sigma, Bristol, UK). Glibenclamide was dissolved in DMSO.
Cromakalim was dissolved in saline. STZ was dissolved in 5 mM
citrate buffer (pH 4.0). All injections were administered at a
volume of 5 ml/kg. Appropriate vehicle controls were performed
for each experiment.
STZ, cromakalim, glibenclamide were administered intraper-
itoneally (i.p.). To assess clonic seizure experiments, PTZ was
administered intravenously (0.5%, i.v.). The doses were chosen
based on previously published studies7,8 and pilot experiments.
2.2. Experimental animals
Male NMRI mice weighing 20–25 g (Pasteur Institute) were
used throughout this study. Animals were housed in groups of 4–5
andwere allowed free access to food andwater except for the shorttime that animals were removed from their cages for testing. All
behavioral experiments were conducted during the period
between 10:00 and 13:00 with normal room light (12 h regular
light/dark cycle) and temperature (22  1 8C). All procedures were
carried out in accordance with the institutional guidelines for animal
care and use.
Animals were made insulin-dependent diabetic (type I) by
intraperitoneal injection of 140 mg/kg STZ47; which was dissolved
in 5 mM citrate buffer (pH 4.0). Control animals only received
citrate buffer. After 24 h following STZ administration, blood
samples were taken from tail vein and hyperglycemia was
conﬁrmed by measuring blood glucose levels, using a glucometer
(GlucoMen Glyco´, A. Menarini Industrie Farmacutiche Riunite
S.R.L., Italy). Animals showing fasting blood glucose higher than
250 mg/dl were considered as diabetic mice. Both vehicle-treated
and STZ-induced diabetic animals were randomly divided up into
seven groups of 0-, 3-day and 1-, 2-, 4-, 6- and 8-week
experimental groups. Each group consisted of 8–10 animals.
Subsequent analysis of serumwas performed at the time of seizure
threshold determination in each group.
2.3. Determination of clonic seizure threshold
PTZ-induced clonic seizure threshold was determined by
inserting a 30-gauge butterﬂy needle into the tail vein of mice
and the infusion of PTZ (0.5%) at a constant rate of 1 ml/min to
unrestrained freely moving animals. Infusion was halted when
forelimb clonus followed by full clonus of the body was observed.
Minimal dose of PTZ (mg/kg of mice weight) needed to induce
clonic seizure was considered as an index of seizure threshold. As
such, seizure threshold is dependent on PTZ dose administered and
time-related.7,8,48
2.4. Statistical analysis
Data are expressed as mean  SEM of clonic seizure threshold in
each experimental group. The one-way or two-way analysis of
variance (ANOVA) followed byNewman–Keuls post hoc testwas used
to analyze the data. P < 0.05 was considered the signiﬁcance level
between the groups.
3. Results
Table 1 shows the values of blood glucose and body weight of
age-matched control and diabetic mice at different times after
induction of diabetes by STZ. Compared with non-diabetic mice,
diabetic animals had a signiﬁcant increase in their blood glucose 3
days after STZ injection (143  4.5 mg/dl vs 365.8  70 mg/dl;
P < 0.001) which was persistent afterwards. Also, 2 weeks after
induction of diabetes, diabetic animals (23.5  0.88 g) signiﬁcantly
had less body weight in comparison with 2-week (31.3  0.01 g;
P < 0.05) control animals and this difference was persistent after-
wards.
3.1. Clonic seizure threshold (CST) in control and diabetic mice
Fig. 1 shows the PTZ-induced CST in either non-diabetic or
diabetic mice at different times after injection of vehicle (citrate
buffer) or STZ, respectively. There was no signiﬁcant difference
between the CST induced by PTZ in non-diabetic mice at different
times after vehicle (buffer) injection (F6,45 = 0.1849; P > 0.05).
However, the PTZ-induced CST was interestingly increased in the
3-day, 1- and 2-week diabetic groups compared with correspond-
ing age-matched control mice (F7,51 = 13.46; P < 0.0001; Fig. 1).
The highest level of CST was observed 2 weeks after induction of
diabetes compared to 2-week control group (53.175  4.117 mg/kg
Table 1
Blood glucose (mg/dl) and bodyweight (g) of separate groups of control and diabetic mice 0 and 3 days, 1, 2, 4, 6 and 8weeks after injection of either citrate buffer (control) or
streptozocine (diabetic).
0-day 3-day 1-week 2-week 4-week 6-week 8-week
Blood glucose (mg/dl)
Non-diabetic
138.43.4 1434.5 135.66.7 139.87.6 146.910.2 142.612 13610
Diabetic
1423.2 365.870b 34966.5a 426.8731b 54153.7b 537.837b 489.447.4b
Body weight (g)
Non-diabetic
23.3 0.47 24.50.59 27.341.2 31.3 0.01 35.20.8 391.07 41.1 0.81
Diabetic
24.3 0.42 26.41.4 23.81.6 23.5 0.88b 23.91.13b 25.21.2b 32.11.44b
Data are expressed as mean SEM. Each group consisted of 10 animals.
a P<0.05 compared with corresponding age-matched control group.
b P<0.001 compared with corresponding age-matched control group.
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was signiﬁcantly (P < 0.001) decreased in 4- and 6-week diabetic
mice compared with 2-week diabetic groups and the CST in these
groups was similar to 4- and 6-week control animals, respectively.
The PTZ-induced CST in 8-week diabetic group (25  2.10 mg/kg)was
lower than 8-week control mice (31  2.21 mg/kg) but the difference
was not signiﬁcant (P > 0.05; Fig. 1).
3.2. Effect of cromakalim and glibenclamide on CST in
non-diabetic control mice
In this step we examined the effect of different doses of the
ATP-sensitive K+ channel opener cromakalim (0 [saline], 0.1, 1, 10
and 30 mg/kg, i.p.) on the CST in non-diabetic control mice.
Cromakalim or its vehicle (saline) was injected 30 min before PTZ.
As shown in Fig. 2A, cromakalim signiﬁcantly increased the CST in
a dose-dependent manner (F4,35 = 3.571; P = 0.0152). Compared
with the saline-treated control non-diabetic group, 30 mg/kg
cromakalim signiﬁcantly (P < 0.01) increased the seizure thresh-
old, whereas lower doses of cromakalim, such as 10 mg/kg, had no
signiﬁcant effect on theCST. Thedose of 10 mg/kg cromakalimwas
considered as a sub-effective or non-effective dose for the next
experiments.
As shown in Fig. 2B, the ATP-sensitive K+ channel blocker
glibenclamide at 0.5 and 1 mg/kg had no signiﬁcant effects on theFig. 1. Comparison of clonic seizure threshold in age-matched control (CN, upper)
and streptozocin (STZ)-induced diabetic (DM, lower) rats at different times after
injection of vehicle (buffer) or STZ, respectively. Each point represents the
mean  SEM of 10mice. *P < 0.05 and ***P < 0.001 comparedwith corresponding age-
matched non-diabetic control groups; ##P < 0.01 and ###P < 0.001 compared with 2-
week diabetic groups.CST in control mice. Glibenclamide was injected into mice 35 min
before PTZ injection. However, glibenclamide at 1 mg/kg (i.p.)
signiﬁcantly (P < 0.05) prevented the enhancing effects of
cromakalim (30 mg/kg) on the CST when injected 5 min before
cromakalim administration (F5,42 = 6.285; P < 0.001).Fig. 2. (A) Effect of cromakalim (Crm, 0.1, 1, 10 and 30mg/kg, i.p.) or its vehicle
(saline) on the PTZ-induced seizure threshold in non-diabetic control mice. (B)
Effect of glibenclamide (Glb, 0.5 and 1 mg/kg, i.p.) or its vehicle (DMSO) on the PTZ-
induced seizure threshold in non-diabetic controlmice 5 min before either saline or
cromakalim (30 mg/kg, i.p.) injection. Each point represents the mean  SEM of 10
mice. **P < 0.01 compared with corresponding control group. #P < 0.05 compared
with vehicle (DMSO)/cromakalim (Crm, 30 mg/kg) group.
Fig. 3. Effect of glibenclamide (Glb, 1 mg/kg, i.p.) or its vehicle (DMSO) on the PTZ-
induced seizure threshold in either 2-week control (buffer) or diabetic (STZ) mice,
alone or in combinationwith cromakalim (Crm, 10 mg/kg, i.p.) or its vehicle (saline).
Each point represents the mean  SEM of 10 mice. **P < 0.01 and ***P < 0.001
compared with corresponding non-diabetic control group; ###P < 0.001 compared
with saline/vehicle 2-week diabetic group. ++P < 0.01 compared saline/Glb (1 mg/kg)
2-week diabetic group.
Fig. 4. Effect of cromakalim (Crm, 10mg/kg, i.p.) or its vehicle (saline) on the PTZ-
induced seizure threshold in either 8-week control (buffer) or diabetic (STZ) mice,
alone or in combination with glibenclamide (Glb, 1 mg/kg, i.p.) or its vehicle
(DMSO). Each point represents the mean  SEM of 10mice. #P < 0.05 compared with
vehicle/saline 8-week diabetic group. +P < 0.05 compared vehicle/Crm (10 mg/kg, i.p.)
8-week diabetic group.
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diabetic mice
In this step we examined the role of glibenclamide in the
elevated CST in 2-week diabetic animals. Glibenclamide or its
vehicle (DMSO) was injected 30 min before PTZ. As shown in Fig. 3,
glibenclamide at 1 mg/kg (i.p.) had no signiﬁcant effect on the PTZ-
induced CST in 2-week control animals. However, it signiﬁcantly
(P < 0.001) decreased the PTZ-induced CST in 2-week diabetic
animals compared with vehicle-injected diabetic ones. The PTZ-
induced CST was similar between glibenclamide-injected 2-week
diabetic animals and 2-week non-diabetic controls. Glibenclamide
(1 mg/kg, i.p.) or its vehicle had no signiﬁcant effect on the blood
glucose in either control or diabetic mice (data not shown).
The decreasing effect of glibenclamide (1 mg/kg, i.p.) on the CST
in 2-week diabetic mice was prevented by pre-treatment with the
ATP-sensitive K+ channel opener cromakalim (10 mg/kg, i.p.).
Cromakalimwas injected into themice 5 min before glibenclamide
injection and 35 min before PTZ. Moreover, cromakalim at the
same dose, alone or in combination with glibenclamide (1 mg/kg,
i.p.), had no signiﬁcant effect on the CST in non-diabetic control
mice (Fig. 3). Cromakalim (10 mg/kg, i.p.) or its vehicle alone or in
combination with glibenclamide had no signiﬁcant effect on the
blood glucose in either control or diabetic mice (data not shown).
3.4. Effect of glibenclamide and cromakalim on CST in 8-week
diabetic mice
In this step we ﬁrst examined the effect of cromakalim on the
CST in 8-week diabetic animals. Cromakalim or its vehicle (saline)
was injected 30 min before PTZ. As shown in Fig. 4, cromakalim at
10 mg/kg (i.p.) had no signiﬁcant effect on the PTZ-induced CST in
8-week control animals. However, it signiﬁcantly (P < 0.05)
increased the PTZ-induced CST in 8-week diabetic animals
compared with vehicle-injected diabetic ones. The PTZ-induced
CST was similar between cromakalim-injected 8-week diabetic
animals and 8-week non-diabetic controls. Cromakalim (10 mg/kg,
i.p.) or its vehicle had no signiﬁcant effect on the blood glucose in
either control or diabetic mice (data not shown).As shown in Fig. 4, the increasing effect of cromakalim (10 mg/
kg, i.p.) on the CST in 8-week diabetic mice was prevented by pre-
treatment with glibenclamide (1 mg/kg, i.p.). Glibenclamide was
injected into the mice 5 min before cromakalim injection and
35 min before PTZ. Moreover, glibencalmide at the same dose,
alone or in combination with cromakalim (10 mg/kg, i.p.), had no
signiﬁcant effect on the CST in 8-week non-diabetic controls.
Glibenclamide (1 mg/kg, i.p.) or its vehicle alone or in combination
with cromakalim (10 mg/kg, i.p.) had no signiﬁcant effect on the
blood glucose in either 8-week control or diabetic mice (data not
shown).
4. Discussion
In the present study, we found that in the STZ-induced diabetic
mice, the threshold of PTZ-induced clonic seizures is increased in a
time-dependent manner and this elevation reaches a peak on the
secondweek after induction of diabeteswith STZ injection.We also
demonstrated that the PTZ-induced seizure threshold was
signiﬁcantly decreased in 4-, 6- and 8-week diabetic mice in a
time-dependent manner compared with 2-week diabetic animals.
The seizure threshold in 8-week diabeticmicewas even lower than
the 8-week non-diabetic control mice, though the difference was
not signiﬁcant. Our data also revealed that the non-effective dose
of KATP channel blocker glibenclamide prevented the increased
seizure threshold in 2-week diabetic mice and this effect of
glibenclamide was blocked by pre-treatment with the selective
KATP channel opener cromakalim. Additionally, cromakalim sig-
niﬁcantly increased the seizure threshold in 8-week diabetic mice
but not age-matched non-diabetic mice and this effect of
cromakalimwas inhibitedwith pre-treatment with glibenclamide.
These data for the ﬁrst time demonstrate that KATP channels are
involved in the time-dependent alteration in the PTZ-induced
seizure threshold in diabetic mice.
It is well known that KATP channels play a pivotal role in the
modulation of seizure threshold.49 Cromakalim has been shown to
reduce excitability in CA3 hippocampal cells50 and to display
antiepileptic properties in a model of drug-induced epilepsia.10,51
Mice with deﬁciencies in expression of either the SUR1 gene or the
Kir6.1 gene are vulnerable to kainic acid-induced seizures, an
animal model of human temporal lobe epilepsy.52 Soundarapan-
dian et al. have also demonstrated that expression of functional
Kir6.1/SUR1 channels can be considered as an endogenous cellular
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danger of over-stimulation of glutamate transmission at CA3
synapses.53 Pharmacological studies have demonstrated that KATP
channels play an important role in the control of seizure threshold
in several in vitro and in vivomodels.3,7–12,54 Moreover, it has been
shown that mice lacking a subunit of KATP channels (Kir 6.2
/
mice) are vulnerable to hypoxia, exhibiting a reduced threshold for
generalized seizure.9 Transgenic mice, overexpressing the SUR1
gene in the forebrain, show a signiﬁcant increase in the threshold
for kainate-induced seizures.13 Consistently, we have recently
reported that KATP channel openers such as cromakalim and
diazoxide increased the clonic seizures induced by PTZ in mice.7,8
The PTZ-induced clonic seizures primarily model a type of
forebrain-regulated seizures that are associated with increased
activity in major epileptogenic centers of forebrain like amygdala
and piriform cortex.55–57
In the present study, we showed that in diabetic mice the PTZ-
induced seizure threshold was altered in a time-dependent
manner, reaching a peak on week 2 after STZ injection and
declining afterwards. Although these data suggest that the period
of experimental diabetes seems to play an important role in the
observed effects of diabetes on the PTZ-induced seizure threshold,
previous studies have shown that the seizure susceptibility is
increased in diabetic animals.29–32 This differences in results could
be explained by the fact that in the present study we used the PTZ
model of seizure threshold in mice which is different with the
previous studies. We interestingly demonstrated that a non-
effective dose of the speciﬁc KATP channel blocker could inhibit the
increased seizure threshold induced by PTZ in 2-week diabetic
mice and a non-effective dose of the selective KATP channel opener
cromakalim increased the seizure threshold in 8-week diabetic
mice, suggesting that KATP channels may play an essential role in
the time-dependent alterations in the seizure threshold in diabetic
mice. In agreement with this assumption, several line of evidence
have indicated that the alterations in the KATP channel functioning
in diabetic condition is dependent on the duration of the disease.
For instance, Kersten et al. have found that the dilation of small
coronary arteries induced by the KATP channel opener was
increased in alloxan-induced 1-week diabetic dogs.40 Ikenaga et
al. also reported that only 2 weeks after STZ injection, rat isolated
renal afferent arterioles exhibited exaggerated responses to the
KATP channels openers pinacidil and PCO-400.
43 They suggested
that the functional availability of afferent arteriolar KATP channels
may be increased during the early stage of diabetes, or that the
impact of these channels on membrane potential is exaggerated.43
In our recent study, a signiﬁcant enhancement in the cromakalim-
induced relaxation of isolated corpus cavernosumwas observed in
2-week diabetic rats, whereas the relaxant responses to croma-
kalim were decreased in 6- and 8-week diabetic rats.44 According
to these reports and considering the anticonvulsant property of
KATP channel activation, it could be suggested that the enhanced
seizure threshold in 2-week diabetic mice in the present study
could be due to the enhanced activity of central KATP channels,
since a non-effective dose of glibenclamide could prevent this
enhancement. An increased KATP channel activity at this time may
be associated with a very high metabolic state (i.e. low ATP levels)
of cells relatively soon after the initiation of hyperglycemia. This is
in line with the fact that KATP channels are gated by intracellular
ATP/ADP concentrations6,58 coupling cell metabolic events to
electrical activity.59 However, this general assumption has to await
more detailed studies evaluating the activity of KATP channels in
brain regions especially forebrain that is associated with the
seizures induced by PTZ.
Our data also revealed that compared to the 2-week diabetic
animals seizure threshold was signiﬁcantly decreased in 4-, 6- and
8-week diabetic animals. The seizure threshold was even lowerthat control levels in 8-week diabetic mice, though it was not
signiﬁcant. The deterioration in the seizure threshold could be
discussed by the profound effects of diabetic condition on the
central nervous system. Accordingly, several studies have shown
that in the adult diabetic patients hyperglycemia can precipitate
seizures.19–28 Animal studies also demonstrated that alloxan-
induced diabetic hyperglycemia was associated with proconvul-
sant effects in the electroshock seizure model in the adult rats29
and mice.30 These observations could be explained by the
adverse effects of long-term hyperglycemia on the seizure
threshold in diabetic patients.27,31 We interestingly observed that
the non-effective dose of cromakalim increased the seizure
threshold in 8-week diabetic mice and this effect was blocked
by glibenclamide. This might reﬂect a gradual deterioration of the
function of KATP channels during progression of diabetes. In
agreement with this assumption, there is convincing evidence that
relaxant responses to the KATP channel openers are decreased in a
variety of tissues from long-term diabetic animals including rat
corpus cavernosum,44 thoracic aorta,60 basilar arteries39 and
cerebral arteries.35,36 Some studies also reported that chronic
hyperglycemia induced a reduction in KATP channel gene expres-
sion in the pancreas.61–63 By linking neuronal metabolism and
excitability KATP play an important role in protecting cells from
neuronal death caused by hypoxia, ischemia or metabolic
inhibition. Increased KATP channel activity in blood vessels during
metabolic stress, such as during ischemia, could have a helpful
effect on the maintenance of tissue perfusion. In this regard,
Yamada et al. even reported that KATP channels have protective
role in the hypoxia-induced generalized seizure.9 Therefore, it is
reasonable to suggest that tissues could more susceptible to
ischemic damage after extended periods of diabetes owing to
impaired function of KATP channels. Consistently,
64 have shown
that both hypoxia-induced and aprikalim (a KATP channel opener)-
induced vasodilation of coronary arterioles were impaired in
patients with both Type I and Type II diabetes. They also showed
that KATP channel blockade by glibenclamide reduced hypoxic
vasodilation, suggesting that KATP channels are involved in
transducing vascular signals to reduced tissue oxygen concentra-
tions in the human heart. Since impairment in the function of
vascular system is one of the complications of long-standing
diabetes, this even could affect the function of central nervous
system and increase the seizure susceptibility via disturbing KATP
channels functioning. Taken our results together with previous
studies, it could be suggested that the decrease in the PTZ-induced
seizure threshold in chronic diabetic mice might be due to either
decrease in the activity or expression of KATP channels in the brain
regions modulating the seizure susceptibility. However, more
studies are clearly needed to verify this assumption.
In conclusion, in the present study we demonstrated a time-
dependent alteration in the seizure threshold in diabetic mice,
reaching a peak on week 2 after STZ injection and declining
afterwards. We also indicated that the alteration in the KATP
channel functioning during the diabetic state could be involved in
this manner.
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